GlobeNewswire: Catalyst Pharmaceuticals, Inc. Contains the last 10 of 372 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:00:06ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853962/0/en/Catalyst-Pharmaceuticals-Announces-Support-for-the-Inaugural-Lambert-Eaton-Myasthenic-Syndrome-LEMS-Awareness-Day.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day2024-03-28T12:03:00Z<![CDATA[CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the LEMS community. The chosen date holds profound historical significance, coinciding with the publication of Dr. Edward Lambert and Dr. Lee Eaton's pioneering research on LEMS, which has greatly advanced the understanding and treatment of this rare neuromuscular disorder.]]>https://www.globenewswire.com/news-release/2024/03/27/2853130/0/en/Catalyst-Pharmaceuticals-to-Participate-in-the-2024-Cantor-Virtual-Muscular-Dystrophy-Symposium.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium2024-03-27T12:03:00Z<![CDATA[CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.]]>https://www.globenewswire.com/news-release/2024/03/13/2845339/0/en/Catalyst-Pharmaceuticals-Announces-AGAMREE-Now-Commercially-Available-in-the-U-S-for-the-Treatment-of-Duchenne-Muscular-Dystrophy-DMD.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)2024-03-13T11:55:00Z<![CDATA[AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile]]>https://www.globenewswire.com/news-release/2024/03/05/2840420/0/en/Catalyst-Pharmaceuticals-to-Participate-at-the-Barclays-26th-Annual-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference2024-03-05T13:03:00Z<![CDATA[CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference being held in Miami on March 12-14, 2024.]]>https://www.globenewswire.com/news-release/2024/02/28/2837533/0/en/Catalyst-Pharmaceuticals-Reports-Strong-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update2024-02-28T23:03:23Z<![CDATA[Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022]]>https://www.globenewswire.com/news-release/2024/02/27/2835996/0/en/Catalyst-Pharmaceuticals-to-Present-at-MDA-Clinical-Scientific-Conference-Details-of-Registry-for-Study-of-Long-Term-Safety-and-Quality-of-Life-in-Duchenne-Muscular-Dystrophy-Patie.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE2024-02-27T13:03:00Z<![CDATA[CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced an upcoming poster about the establishment of a registry to study long-term safety and quality of life (QoL) in patients with Duchenne muscular dystrophy (DMD) who are treated with AGAMREE® (vamorolone) at the upcoming 2024 MDA Clinical & Scientific Conference taking place March 3-6 in Orlando.]]>https://www.globenewswire.com/news-release/2024/02/21/2832813/0/en/Catalyst-Pharmaceuticals-Announces-Publication-of-Santhera-Pharmaceutical-s-VISION-DMD-Vamorolone-AGAMREE-Study-Results-in-the-Peer-Reviewed-Journal-Neurology.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology2024-02-21T14:00:00Z<![CDATA[Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of Vamorolone Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of Vamorolone]]>https://www.globenewswire.com/news-release/2024/02/14/2829058/0/en/Catalyst-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-28-2024.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 20242024-02-14T13:03:00Z<![CDATA[The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET]]>https://www.globenewswire.com/news-release/2024/01/09/2806674/0/en/Catalyst-Pharmaceuticals-Inc-Announces-Closing-of-Public-Offering.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering2024-01-09T21:05:13Z<![CDATA[CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of shares of its common stock. The Company sold 10,000,000 shares of its common stock in the offering at a public offering price of $15.00 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of the Company's common stock at the public offering price, less underwriting discounts.]]>https://www.globenewswire.com/news-release/2024/01/05/2804622/0/en/Catalyst-Pharmaceuticals-Inc-Announces-Pricing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=11345Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock2024-01-05T13:02:06Z<![CDATA[CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $150,000,000, before deducting underwriting discounts and expenses payable by Catalyst. Catalyst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is expected to close on or about January 9, 2024, subject to customary closing conditions. All of the shares in the offering are being sold by Catalyst.]]>